Supernus Pharmaceuticals (NasdaqGM:SUPN) FY Conference Transcript

Supernus Pharmaceuticals FY Conference Summary Company Overview - Company: Supernus Pharmaceuticals (NasdaqGM: SUPN) - Date of Conference: March 11, 2026 - Key Speaker: Jack A. Khattar, President and CEO Key Accomplishments in 2025 - Sage Therapeutics Acquisition: Significant milestone for the company, enhancing the product portfolio with the addition of Zurzuvae, which is expected to be a major growth driver [2][4] - FDA Approvals and Product Launches: Successful launch of ONAPGO, which exceeded expectations and contributed to revenue growth [4][5] - Record Revenue: 2025 marked a record year for revenue, driven by the transition from legacy products to new offerings [4] Growth Drivers - Product Portfolio: Four main growth drivers identified: - Qelbree: ADHD treatment, showing 21% growth in 2025 and 18% growth in Q4 [5][23] - Gocovri: Parkinson's treatment, with 14% growth in prescriptions [37] - Zurzuvae: Postpartum depression treatment, unique in its rapid efficacy [38] - ONAPGO: Strong demand despite supply constraints, with forms submitted increasing from 1,300 to 1,800 [10][49] Market Performance - Stock Performance: The stock increased by 80% over a six-month period, reflecting market recognition of the company's portfolio reconfiguration [12] - Market Share: Qelbree achieved 931,000 prescriptions in 2025, indicating significant market potential within a total market of 111 million prescriptions [27] Supply Chain and Production - Supply Constraints: ONAPGO faced supply issues due to overwhelming demand and shared production lines with other clients [48] - Future Supply Plans: Plans to secure a second source of supply by 2027 to alleviate production constraints [49] Financial Guidance for 2026 - Revenue Expectations: Projected revenue between $840 million and $870 million, representing a growth of 32%-37% [50] - Operating Earnings: Expected to remain flat year-over-year at $140 million to $170 million due to ongoing investments in new products [58] Research and Development Pipeline - SPN-817: Phase 2 trial for epilepsy, expected data in 2027 [68][72] - SPN-820: Phase 2 trial for major depressive disorder, anticipated to recruit faster than epilepsy trials [74] - SPN-443: Early-stage stimulant for ADHD, with ongoing studies to assess its safety and efficacy [78] Strategic Outlook - M&A and R&D: The company emphasizes the importance of both mergers and acquisitions and research and development for future growth [93] - Market Education: Ongoing efforts to educate physicians and patients about new treatment options, particularly for postpartum depression [61][66] Conclusion - Future Potential: The company believes it is at the beginning of a transformative phase, with a clean balance sheet and a focus on both organic growth and strategic acquisitions [93]